Monoclonal antibody

Intraveinous route of administration - monthly administration

Companion biomarkers - inclusion tool

ENCEFA has identified an unprecedented mechanism of action by modulating CD38 (specific epitope), an age-related target highly expressed in the brain and the immune system, whose expression is highly dysregulated in neuro-degenerative and auto-immune diseases.

While drugs currently under development directly involve a unique pathway at a time, our antibodies trigger pleiotropic strong beneficial effects by regulating through its target autophagy, metabolism and inflammation, three shared key deleterious mechanisms at play in several age-related diseases.

Among these beneficial effects, strong neuro-protection and immuno-modulation have been shown in several preclinical in vivo models, including preliminary results in post-conditioning (when disease is installed). 

Thus, ENCEFA's antibody represents a promising advance against neuro-degenerative pathologies, facing the complexity of these pathologies in a clinical stage.

ENCEFA's first indication will be the Amyotrophic Lateral Sclerosis. First human clinical trials are planned to be launched in Q3 2021, with the ambition to tackle a wide scope of neuro-degenerative and auto-immune diseases, to finally adress ageing process in a preventive setting.